Results 251 to 260 of about 32,390 (296)

Simple cardiac hypertrophy? More needs to be done to explain the cause of HFpEF

Jakub Mrzyk, Marek Klocek, Wiktoria Wojciechowska, Bernadetta Chyrchel, Marek Rajzer   +4 more
openalex   +2 more sources

Applicability and Clinical Utility of Framingham and NHANES criteria in HFrEF HFpEF and Combined HF

, 2019
Dhanasegaran Sivanesan Egambaram, N. Swaminathan, S. Venkatesan   +2 more
openalex   +1 more source

Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration

European Journal of Heart Failure, EarlyView.
Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.
Jakob Versnjak, Titus Kuehne, Pauline Fahjen, Nina Jovanovic, Ulrike Löber, Gabriele G. Schiattarella, Nicola Wilck, Holger Gerhardt, Dominik N. Müller, Frank Edelmann, Philipp Mertins, Roland Eils, Michael Gotthardt, Sofia K. Forslund, Benjamin Wild, Marcus Kelm   +15 more
wiley   +1 more source

Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction

European Journal of Heart Failure, EarlyView.
Mohammad A. Almesned, Bart J. van Essen, Johanna. E. Emmens, Jasper Tromp, Marcelle D. Smit, Christiane A. Geluk, Ron T. Gansevoort, Stephan. J.L. Bakker, Kevin Damman, Rudolf A. de Boer, Dirk J. van Veldhuisen, Adriaan A. Voors, Erik Lipsic   +12 more
wiley   +1 more source

European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure

European Journal of Heart Failure, EarlyView.
The patient with SMR: From diagnostic assessment to treatment. Secondary mitral regurgitation (SMR) is highly prevalent in patients with heart failure (HF), associated with poor prognosis, and its treatment is typically preceded by implementing pharmacotherapy for HF as well as cardiac resynchronization therapy.
Christos Iliadis, Marianna Adamo, Volker Rudolph, Nicole Karam, Ralph Stephan von Bardeleben, Stefan D. Anker, Victoria Delgado, Jörg Hausleiter, Hannah Kempton, Marco Metra, Michael Böhm, Stephan Baldus   +11 more
wiley   +1 more source

Early Changes in Cardiac Macrophage Subsets in Heart Failure with Preserved Ejection Fraction. [PDF]

Int J Mol Sci
Gutiérrez D, Cordero K, Sepúlveda R, Venegas C, Altamirano D, Candia C, Ramírez G, Araos P, Amador CA, Hermoso MA, Gabrielli L, Jalil JE, Ocaranza MP.   +12 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction

European Journal of Heart Failure, EarlyView.
Aims Mineralocorticoid receptor antagonists (MRAs) are often underused in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Individual treatment effect (ITE) may assist physicians in making timely decisions about which patients are the best suited for personalized therapy.
Masatake Kobayashi, Kevin Duarte, João Pedro Ferreira, Guillaume Baudry, Luca Monzo, John J.V. McMurray, Dirk J Van Veldhuisen, Bertram Pitt, Faiez Zannad, Nicolas Girerd   +9 more
wiley   +1 more source

Improving Recognition of Heart Failure With Preserved Ejection Fraction in the Outpatient Setting: A Pilot Study of Readily Useful Clinical Attributes. [PDF]

Cureus
Sawalha K, Rana A, Alamat L, Fancher AJ, Albadaineh M, Lopez-Candales A, Asif T.   +6 more
europepmc   +1 more source

Cardiopulmonary Exercise Testing and HFpEF: Diagnostic and Therapeutic Perspectives

Francesco Di Spigno, Valeria Dall’Ospedale, Luigi Gerra, Federico Breviario, Andrea Tedeschi, Giancarlo Trimarchi, Daniela Aschieri   +6 more
openalex   +1 more source

Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme

European Journal of Heart Failure, EarlyView.
Abstract Background The prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age, and older adults with HFpEF have worse physical function, quality of life, and clinical outcomes. Semaglutide demonstrated efficacy in the treatment of obesity‐related HFpEF in the STEP‐HFpEF trials.
Ambarish Pandey, Michael Moroney, Subodh Verma, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Sanjiv J. Shah, Mark C. Petrie, Cecilia Rönnbäck, Anne Domdey, Søren Rasmussen, Khaja M. Chinnakondepalli, Shachi Patel, Mikhail N. Kosiborod   +14 more
wiley   +1 more source